MIOKARPIN 2% Kapi za oči, rastvor Montenegro - kroatiska - CInMED-Institut za ljekove i medicinska sredstva Crne Gore

miokarpin 2% kapi za oči, rastvor

druŠtvo sa ograniČenom odgovornoŠĆu "hemomont" za proizvodnju farmaceutskih proizvoda podgorica - pilokarpin - kapi za oči, rastvor - 2%

SINOXAL 100mg Prašak za rastvor za infuziju Montenegro - kroatiska - CInMED-Institut za ljekove i medicinska sredstva Crne Gore

sinoxal 100mg prašak za rastvor za infuziju

"evropa lek pharma" doo podgorica - oksaliplatin - prašak za rastvor za infuziju - 100mg

SINOXAL 50mg Prašak za rastvor za infuziju Montenegro - kroatiska - CInMED-Institut za ljekove i medicinska sredstva Crne Gore

sinoxal 50mg prašak za rastvor za infuziju

"evropa lek pharma" doo podgorica - oksaliplatin - prašak za rastvor za infuziju - 50mg

EXODERIL 1% Rastvor za kožu Montenegro - kroatiska - CInMED-Institut za ljekove i medicinska sredstva Crne Gore

exoderil 1% rastvor za kožu

druŠtvo za trgovinu na veliko farmaceutskim proizvodima "glosarij" d.o.o.-podgorica - naftifin - rastvor za kožu - 1%

Angiox Europeiska unionen - kroatiska - EMA (European Medicines Agency)

angiox

the medicines company uk ltd - Бивалирудин - akutni koronarni sindrom - antitrombotska sredstva - angiox predstavljena kao антикоагулянта kod odraslih pacijenata koji su patili чрескожное koronarne intervencije (ЧКВ), uključujući i kod bolesnika sa st-segmenta visina infarkta miokarda (stemi) prolazi primarni ЧКВ. angiox je također indiciran za liječenje odraslih bolesnika s nestabilnom anginom / nedostatak segmenta st инфарктом miokarda (val / ami bez elevacije st segmenta), planiranih za hitnu ili rane intervencije. angiox treba propisati aspirin i клопидогрел.

Clopidogrel Viatris (previously Clopidogrel Taw Pharma) Europeiska unionen - kroatiska - EMA (European Medicines Agency)

clopidogrel viatris (previously clopidogrel taw pharma)

viatris limited - klopidogrel besilat - peripheral vascular diseases; stroke; myocardial infarction - antitrombotska sredstva - secondary prevention of atherothrombotic events clopidogrel is indicated in:adult patients suffering from myocardial infarction (from a few days until less than 35 days), ischemic stroke (from 7 days until less than 6 months) or established peripheral arterial disease. adult patients suffering from acute coronary syndrome. non-st segment elevation acute coronary syndrome (unstable angina or non-q-wave myocardial infarction), including patients undergoing a stent placement following percutaneous coronary intervention, in combination with acetylsalicylic acid (asa). porastom segmenta st akutni infarkt miokarda, u kombinaciji s ask u liječenju pacijenata koji imaju pravo na thrombolytic terapije. in patients with moderate to high-risk transient ischaemic attack (tia) or minor ischaemic stroke (is) clopidogrel in combination with asa is indicated in:adult patients with moderate to high-risk tia (abcd2 score ≥4) or minor is (nihss ≤3) within 24 hours of either the tia or is event. prevention of atherothrombotic and thromboembolic events in atrial fibrillation:in adult patients with atrial fibrillation who have at least one risk factor for vascular events, are not suitable for treatment with vitamin k antagonists (vka) and who have a low bleeding risk, clopidogrel is indicated in combination with asa for the prevention of atherothrombotic and thromboembolic events, including stroke. za više informacija, molimo pogledajte odjeljak 5.